RemeGen Ltd. has obtained China’s first approval for an antibody-drug conjugate (ADC) oncologic for Aidixi (disitamab vedotin), to treat patients with locally advanced or metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, who have received at least two types of chemotherapy.
China’s First ADC Secures Domestic Approval
Gastric Cancer Nod
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
